Zenabis Global (TSX:ZENA) posted net revenue of $11.6-million from its cannabis and propogation segment for the first quarter of 2019, up from $3.4-million in the fourth quarter of 2018, which included only its cannabis...
BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...
Closely-held Scientus Pharma received authorization under Health Canada’s cannabis regulations for the sale of cannabis oils and capsules for medical purposes. The company previously obtained its Health Canada license...
OncoSec Medical (NASDAQ:ONCS) dosed the first patient in a trial assessing a triple drug combination, which includes OncoSec’s TAVO, in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer...
The FDA approved REGENXBIO’s (NASDAQ:RGNX) ZOLGENSMA for the treatment of spinal muscular atrophy (SMA) in pediatric patients who are less than two years of age. Caused by a genetic defect in the SMN1 gene, SMA is...
Neovasc (NASDAQ:NVNC) reported positive long term safety and efficacy data for its Reducer device in 50 patients suffering from refractory disabling angina. Neovasc’s Reducer relives angina symptoms by altering blood...
Iovance Biotherapeutics (NASDAQ:IOVA) LN-145 received FDA breakthrough therapy designation in recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy. Designed to...
Canopy Growth (TSX:WEED; NYSE: CGC) acquired This Works in an all-cash transaction for £43 million. British-based This Works offers a range of high-quality natural skincare and sleep solution products, including deep...
Investment banker Brookline Capital Markets entered into a partnership with broker-dealer, Arcadia Securities. The transaction allows Brookline to capitalize on and expand its growing presence in the public capital...
BeyondSpring’s (NASDAQ:BYSI) abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 2019 conference May 18-22 in New...
The Chinese patent office granted Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) a notice of acceptance for its light activated photodynamic compounds (PDC) intended to safely and effectively destroy various cancers...
The FDA has accepted Abeona Therapeutics (NASDAQ:ABEO) IND application for AB-202 for the treatment of CLN1 disease. CLN1 disease, also known as infantile Batten disease, is caused by a mutation in the PPT1 gene. In...
Oragenics (NYSE American:OGEN) has enrolled more than 80 patients in its Phase 2 trial of AG013 for the treatment of oral mucositis (OM). The company also reported that the WHO provided AG013 with the generic name...
Biocept (NASDAQ:BIOC) launched its multi-gene liquid biopsy panel for the detection of biomarkers associated with lung cancer. The difficulty of obtaining lung tissue samples from patients has previously limited access...
Compugen (NASDAQ:CGEN) dosed the first patient in its Phase 1 trial of COM701, in combination with Opdivo, in patients with advanced solid tumors. The Phase 1 study will assess the safety and tolerability of COM701, a...
Principia Biopharma (NASDAQ:PRNB) reported that PRN1371 was well tolerated in the dose escalation portion of its Phase 1 trial in adult patients with advanced solid tumors. PRN1371, a fibroblast growth factor receptor...
resTORbio (NASDAQ:TORC) reported new data from its Phase 2b trial of RTB101 for the treatment of respiratory tract infections (RTIs) in patients 65 years of age and older. Licensed from Novartis, RTB101 is a TORC1...
Axovant Gene Therapies (NASDAQ:AXGT) has dosed the first patient in a clinical study of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene...
Mustang Bio (NASDAQ:MBIO) and development partner, Nationwide Children’s Hospital (NCH), received FDA orphan drug designation for MB-108 for the treatment of malignant glioma. Malignant glioma is a type of brain cancer...
Achillion Pharmaceuticals (NASDAQ:ACHN) reported interim data from its Phase 2 trial of ACH-4471, in combination with eculizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement...
Two of BeyondSpring’s (NASDAQ:BYSI) abstracts about its lead asset, Plinabulin, were accepted for publication in the proceedings of this year’s ASCO annual meeting May 31 to June 4 in Chicago. The data, derived from...